Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>This is our first report on a Insulet Corporation, one of the largest insulin delivery systems providers in the world.</li><li>Their Omnipod 5 Automated Insulin Delivery System's complete commercial introduction in 2022 was a major accomplishment.</li><li>We initiate coverage on the stock of Insulet Corporation with a 'Hold' rating.</li></ul>

This is our first report on a Insulet Corporation, one of the largest insulin delivery systems providers in the world.Their Omnipod 5 Automated Insulin Delivery System's complete commercial introduction in 2022 was a major accomplishment.We initiate coverage on the stock of Insulet Corporation with a 'Hold' rating.

Insulet Corporation: Initiation of Coverage – Business Strategy & Key Drivers

Equity Capital Markets

Global Healthcare Analyst

Tina Banerjee

Thematic (Sector/Industry)

<ul>
<li>Despite the macroeconomic headwinds, Q3 results from the large medtech companies showed some encouraging signs including healthy procedure volume growth depicting recovery in the medtech sector globally.</li>
<li>Amidst fear of recession, most of these companies reported healthy system placement and no order cancellation. Diabetes, with a large underpenetrated addressable population, remains one of the most resilient segments.</li>
<li>Financial performances of APAC medtech companies are expected to be driven by healthy global procedure volume growth and Fx, partially offset by macroeconomic headwinds including inflation and supply constraints.</li>
</ul>


Despite the macroeconomic headwinds, Q3 results from the large medtech companies showed some encouraging signs including healthy procedure volume growth depicting recovery in the medtech sector globally.
Amidst fear of recession, most of these companies reported healthy system placement and no order cancellation. Diabetes, with a large underpenetrated addressable population, remains one of the most resilient segments.
Financial performances of APAC medtech companies are expected to be driven by healthy global procedure volume growth and Fx, partially offset by macroeconomic headwinds including inflation and supply constraints.


Global Medtech Trends: Readouts from Early Birds of Q3 Earnings Season- Positives and Negatives

Fundamental Short Selling Research

Eric Fernandez, CFA

TwoRiversAnalytics

<ul>
<li>This model looks for slowing growth, margin declines, sales and/or earnings disappointments, troubling working capital trends, poor estimate trends or lowered guidance, among other characteristics.</li>
<li>The key judgement is whether a slowdown is temporary or the beginning of a trend.  These shorts tend to have high valuations and betas.  Multiple compression accelerates the stock’s decline.</li>
<li>Today we are flagging Quanterix, Insulet, Inari Med,  and MercadoLibre</li>
</ul>


This model looks for slowing growth, margin declines, sales and/or earnings disappointments, troubling working capital trends, poor estimate trends or lowered guidance, among other characteristics.
The key judgement is whether a slowdown is temporary or the beginning of a trend.  These shorts tend to have high valuations and betas.  Multiple compression accelerates the stock’s decline.
Today we are flagging Quanterix, Insulet, Inari Med,  and MercadoLibre


Breaking Growth Short Candidates: Quanterix, Insulet, Inari Med, MercadoLibre

<ul>
<li>Our breaking growth model uncovers slowing growth, margin declines, sales and/or earnings disappointments, troubling working capital trends, poor estimate trends or lowered guidance.</li>
<li>These shorts tend to have moderate to higher betas, time horizons of three to twelve months, higher valuations due to historically strong growth and are often “market darlings”.  </li>
<li>The short response, when growth breaks, is based on a downward reassessment of future growth potential frequently aided by multiple compression that accelerates the decline.</li>
</ul>


Our breaking growth model uncovers slowing growth, margin declines, sales and/or earnings disappointments, troubling working capital trends, poor estimate trends or lowered guidance.
These shorts tend to have moderate to higher betas, time horizons of three to twelve months, higher valuations due to historically strong growth and are often “market darlings”.  
The short response, when growth breaks, is based on a downward reassessment of future growth potential frequently aided by multiple compression that accelerates the decline.


United States

Insulet Corporation is a medical device company that develops, manufactures and markets an insulin infusion system for people with insulin-dependent diabetes.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Insulet Corp (PODD US)

Insulet Corporation: Initiation of Coverage – Business Strategy & Key Drivers

This is our first report on a Insulet Corporation, one of the largest insulin delivery systems providers in the world. Their Omnipod 5 Automated...

Baptista Research

Insulet Corporation: Initiation of Coverage – Business Strategy & Key Drivers

This is our first report on a Insulet Corporation, one of the largest insulin delivery systems providers in the world. Their Omnipod 5 Automated...

Baptista Research

Global Medtech Trends: Readouts from Early Birds of Q3 Earnings Season- Positives and Negatives

Q3 results of large U.S. medtech companies recorded procedure volume growth. However, macroeconomic headwinds are expected to prevail. Similar...

Tina Banerjee

Breaking Growth Short Candidates: Quanterix, Insulet, Inari Med, MercadoLibre

Breaking Growth stocks combine declining fundamentals with multiple compression. This week we flag: Quanterix, Insulet, Inari Med, MercadoLibre

Eric Fernandez, CFA

Breaking Growth Short Candidates

Get a glimpse into our short idea generation process through our Breaking Growth model update. This week: Insulet, Generac, Catalent and Wingstop...

Eric Fernandez, CFA

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)